nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0665	0.0906	CbGbCtD
Linagliptin—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0601	0.0819	CbGbCtD
Linagliptin—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0519	0.0707	CbGbCtD
Linagliptin—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0504	0.0687	CbGbCtD
Linagliptin—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0456	0.0621	CbGbCtD
Linagliptin—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0456	0.0621	CbGbCtD
Linagliptin—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0437	0.0595	CbGbCtD
Linagliptin—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0424	0.0577	CbGbCtD
Linagliptin—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0398	0.0543	CbGbCtD
Linagliptin—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0398	0.0543	CbGbCtD
Linagliptin—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.036	0.0491	CbGbCtD
Linagliptin—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.036	0.0491	CbGbCtD
Linagliptin—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0338	0.0461	CbGbCtD
Linagliptin—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0311	0.0424	CbGbCtD
Linagliptin—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0302	0.0411	CbGbCtD
Linagliptin—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0273	0.0372	CbGbCtD
Linagliptin—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0273	0.0372	CbGbCtD
Linagliptin—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0262	0.0357	CbGbCtD
Linagliptin—DPP4—blood plasma—acquired immunodeficiency syndrome	0.00471	0.163	CbGeAlD
Linagliptin—DPP4—lymphoid tissue—acquired immunodeficiency syndrome	0.00183	0.0636	CbGeAlD
Linagliptin—DPP4—digestive system—acquired immunodeficiency syndrome	0.00181	0.0628	CbGeAlD
Linagliptin—DPP4—blood—acquired immunodeficiency syndrome	0.00173	0.0598	CbGeAlD
Linagliptin—DPP4—bone marrow—acquired immunodeficiency syndrome	0.00167	0.0579	CbGeAlD
Linagliptin—DPP4—vagina—acquired immunodeficiency syndrome	0.0016	0.0555	CbGeAlD
Linagliptin—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00154	0.0533	CbGeAlD
Linagliptin—DPP4—lung—acquired immunodeficiency syndrome	0.00151	0.0525	CbGeAlD
Linagliptin—DPP4—nervous system—acquired immunodeficiency syndrome	0.0014	0.0486	CbGeAlD
Linagliptin—DPP4—central nervous system—acquired immunodeficiency syndrome	0.00135	0.0468	CbGeAlD
Linagliptin—Pancreatitis—Nevirapine—acquired immunodeficiency syndrome	0.00127	0.00535	CcSEcCtD
Linagliptin—Pancreatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00123	0.00518	CcSEcCtD
Linagliptin—Pancreatitis—Stavudine—acquired immunodeficiency syndrome	0.00123	0.00517	CcSEcCtD
Linagliptin—Pancreatitis—Abacavir—acquired immunodeficiency syndrome	0.00121	0.00509	CcSEcCtD
Linagliptin—Pain in extremity—Indinavir—acquired immunodeficiency syndrome	0.00117	0.00493	CcSEcCtD
Linagliptin—Nasopharyngitis—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.00474	CcSEcCtD
Linagliptin—Diabetes mellitus—Ritonavir—acquired immunodeficiency syndrome	0.00112	0.00474	CcSEcCtD
Linagliptin—Malnutrition—Amprenavir—acquired immunodeficiency syndrome	0.0011	0.00464	CcSEcCtD
Linagliptin—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00109	0.0377	CbGeAlD
Linagliptin—Urinary tract infection—Stavudine—acquired immunodeficiency syndrome	0.00108	0.00457	CcSEcCtD
Linagliptin—Diabetes mellitus—Saquinavir—acquired immunodeficiency syndrome	0.00108	0.00456	CcSEcCtD
Linagliptin—DPP4—brain—acquired immunodeficiency syndrome	0.00107	0.0371	CbGeAlD
Linagliptin—Pancreatitis—Zidovudine—acquired immunodeficiency syndrome	0.00106	0.00449	CcSEcCtD
Linagliptin—DPP4—lymph node—acquired immunodeficiency syndrome	0.00103	0.0359	CbGeAlD
Linagliptin—Angioedema—Amprenavir—acquired immunodeficiency syndrome	0.00101	0.00424	CcSEcCtD
Linagliptin—Pancreatitis—Indinavir—acquired immunodeficiency syndrome	0.00099	0.00418	CcSEcCtD
Linagliptin—Nasopharyngitis—Efavirenz—acquired immunodeficiency syndrome	0.000987	0.00416	CcSEcCtD
Linagliptin—Hypoglycaemia—Saquinavir—acquired immunodeficiency syndrome	0.000963	0.00406	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Indinavir—acquired immunodeficiency syndrome	0.000939	0.00396	CcSEcCtD
Linagliptin—Myalgia—Amprenavir—acquired immunodeficiency syndrome	0.000937	0.00395	CcSEcCtD
Linagliptin—Immune system disorder—Nevirapine—acquired immunodeficiency syndrome	0.000936	0.00395	CcSEcCtD
Linagliptin—Pancreatitis—Efavirenz—acquired immunodeficiency syndrome	0.000936	0.00395	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Amprenavir—acquired immunodeficiency syndrome	0.00093	0.00392	CcSEcCtD
Linagliptin—Weight increased—Indinavir—acquired immunodeficiency syndrome	0.000919	0.00388	CcSEcCtD
Linagliptin—Hypoglycaemia—Lamivudine—acquired immunodeficiency syndrome	0.000919	0.00388	CcSEcCtD
Linagliptin—Immune system disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000906	0.00382	CcSEcCtD
Linagliptin—Pancreatitis—Delavirdine—acquired immunodeficiency syndrome	0.000895	0.00378	CcSEcCtD
Linagliptin—Immune system disorder—Abacavir—acquired immunodeficiency syndrome	0.00089	0.00375	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Efavirenz—acquired immunodeficiency syndrome	0.000887	0.00374	CcSEcCtD
Linagliptin—Urinary tract infection—Indinavir—acquired immunodeficiency syndrome	0.000875	0.00369	CcSEcCtD
Linagliptin—Malnutrition—Nelfinavir—acquired immunodeficiency syndrome	0.000873	0.00368	CcSEcCtD
Linagliptin—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.000872	0.00368	CcSEcCtD
Linagliptin—Malnutrition—Stavudine—acquired immunodeficiency syndrome	0.000871	0.00367	CcSEcCtD
Linagliptin—Malnutrition—Abacavir—acquired immunodeficiency syndrome	0.000858	0.00362	CcSEcCtD
Linagliptin—Myalgia—Didanosine—acquired immunodeficiency syndrome	0.000854	0.0036	CcSEcCtD
Linagliptin—Arthralgia—Didanosine—acquired immunodeficiency syndrome	0.000854	0.0036	CcSEcCtD
Linagliptin—Infestation—Efavirenz—acquired immunodeficiency syndrome	0.000851	0.00359	CcSEcCtD
Linagliptin—Infestation NOS—Efavirenz—acquired immunodeficiency syndrome	0.000851	0.00359	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Delavirdine—acquired immunodeficiency syndrome	0.000849	0.00358	CcSEcCtD
Linagliptin—Back pain—Nelfinavir—acquired immunodeficiency syndrome	0.000845	0.00356	CcSEcCtD
Linagliptin—Back pain—Stavudine—acquired immunodeficiency syndrome	0.000842	0.00355	CcSEcCtD
Linagliptin—Weight increased—Delavirdine—acquired immunodeficiency syndrome	0.000831	0.00351	CcSEcCtD
Linagliptin—Pancreatitis—Ritonavir—acquired immunodeficiency syndrome	0.000828	0.00349	CcSEcCtD
Linagliptin—Angioedema—Nevirapine—acquired immunodeficiency syndrome	0.000824	0.00348	CcSEcCtD
Linagliptin—Anaphylactic shock—Didanosine—acquired immunodeficiency syndrome	0.000818	0.00345	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Amprenavir—acquired immunodeficiency syndrome	0.000818	0.00345	CcSEcCtD
Linagliptin—Infection—Didanosine—acquired immunodeficiency syndrome	0.000813	0.00343	CcSEcCtD
Linagliptin—Nasopharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.000802	0.00338	CcSEcCtD
Linagliptin—Pancreatitis—Saquinavir—acquired immunodeficiency syndrome	0.000797	0.00336	CcSEcCtD
Linagliptin—Urinary tract infection—Delavirdine—acquired immunodeficiency syndrome	0.000791	0.00334	CcSEcCtD
Linagliptin—Mediastinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000783	0.0033	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.000775	0.00327	CcSEcCtD
Linagliptin—Arthralgia—Nevirapine—acquired immunodeficiency syndrome	0.000768	0.00324	CcSEcCtD
Linagliptin—Myalgia—Nevirapine—acquired immunodeficiency syndrome	0.000768	0.00324	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.000762	0.00322	CcSEcCtD
Linagliptin—Pancreatitis—Lamivudine—acquired immunodeficiency syndrome	0.00076	0.00321	CcSEcCtD
Linagliptin—Cough—Stavudine—acquired immunodeficiency syndrome	0.00076	0.0032	CcSEcCtD
Linagliptin—Malnutrition—Zidovudine—acquired immunodeficiency syndrome	0.000757	0.00319	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Saquinavir—acquired immunodeficiency syndrome	0.000755	0.00319	CcSEcCtD
Linagliptin—Cough—Abacavir—acquired immunodeficiency syndrome	0.000748	0.00316	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Didanosine—acquired immunodeficiency syndrome	0.000746	0.00315	CcSEcCtD
Linagliptin—Myalgia—Nelfinavir—acquired immunodeficiency syndrome	0.000743	0.00314	CcSEcCtD
Linagliptin—Arthralgia—Nelfinavir—acquired immunodeficiency syndrome	0.000743	0.00314	CcSEcCtD
Linagliptin—Arthralgia—Stavudine—acquired immunodeficiency syndrome	0.000741	0.00313	CcSEcCtD
Linagliptin—Myalgia—Stavudine—acquired immunodeficiency syndrome	0.000741	0.00313	CcSEcCtD
Linagliptin—Weight increased—Saquinavir—acquired immunodeficiency syndrome	0.00074	0.00312	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.000738	0.00311	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.000736	0.00311	CcSEcCtD
Linagliptin—Anaphylactic shock—Nevirapine—acquired immunodeficiency syndrome	0.000736	0.0031	CcSEcCtD
Linagliptin—Back pain—Zidovudine—acquired immunodeficiency syndrome	0.000732	0.00309	CcSEcCtD
Linagliptin—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.000732	0.00309	CcSEcCtD
Linagliptin—Immune system disorder—Indinavir—acquired immunodeficiency syndrome	0.00073	0.00308	CcSEcCtD
Linagliptin—Arthralgia—Abacavir—acquired immunodeficiency syndrome	0.00073	0.00308	CcSEcCtD
Linagliptin—Myalgia—Abacavir—acquired immunodeficiency syndrome	0.00073	0.00308	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.000725	0.00306	CcSEcCtD
Linagliptin—Infestation—Saquinavir—acquired immunodeficiency syndrome	0.000725	0.00306	CcSEcCtD
Linagliptin—Infestation NOS—Saquinavir—acquired immunodeficiency syndrome	0.000725	0.00306	CcSEcCtD
Linagliptin—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.000715	0.00302	CcSEcCtD
Linagliptin—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.000704	0.00297	CcSEcCtD
Linagliptin—Malnutrition—Indinavir—acquired immunodeficiency syndrome	0.000704	0.00297	CcSEcCtD
Linagliptin—Anaphylactic shock—Abacavir—acquired immunodeficiency syndrome	0.0007	0.00295	CcSEcCtD
Linagliptin—Infection—Abacavir—acquired immunodeficiency syndrome	0.000695	0.00293	CcSEcCtD
Linagliptin—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000692	0.00292	CcSEcCtD
Linagliptin—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.000691	0.00292	CcSEcCtD
Linagliptin—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.00069	0.00291	CcSEcCtD
Linagliptin—Immune system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00069	0.00291	CcSEcCtD
Linagliptin—Mediastinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000688	0.0029	CcSEcCtD
Linagliptin—Back pain—Indinavir—acquired immunodeficiency syndrome	0.000681	0.00287	CcSEcCtD
Linagliptin—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.00068	0.00287	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Nevirapine—acquired immunodeficiency syndrome	0.00067	0.00283	CcSEcCtD
Linagliptin—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.000665	0.0028	CcSEcCtD
Linagliptin—Cough—Zidovudine—acquired immunodeficiency syndrome	0.00066	0.00279	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.000649	0.00274	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Stavudine—acquired immunodeficiency syndrome	0.000647	0.00273	CcSEcCtD
Linagliptin—Myalgia—Zidovudine—acquired immunodeficiency syndrome	0.000644	0.00272	CcSEcCtD
Linagliptin—Arthralgia—Zidovudine—acquired immunodeficiency syndrome	0.000644	0.00272	CcSEcCtD
Linagliptin—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.000643	0.00271	CcSEcCtD
Linagliptin—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.000643	0.00271	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00064	0.0027	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Abacavir—acquired immunodeficiency syndrome	0.000638	0.00269	CcSEcCtD
Linagliptin—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000636	0.00268	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000635	0.00268	CcSEcCtD
Linagliptin—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000618	0.00261	CcSEcCtD
Linagliptin—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.000615	0.0026	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000615	0.0026	CcSEcCtD
Linagliptin—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000614	0.00259	CcSEcCtD
Linagliptin—Cough—Indinavir—acquired immunodeficiency syndrome	0.000614	0.00259	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000613	0.00259	CcSEcCtD
Linagliptin—Immune system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00061	0.00258	CcSEcCtD
Linagliptin—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000609	0.00257	CcSEcCtD
Linagliptin—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000608	0.00256	CcSEcCtD
Linagliptin—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.000608	0.00256	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000604	0.00255	CcSEcCtD
Linagliptin—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000603	0.00254	CcSEcCtD
Linagliptin—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.0006	0.00253	CcSEcCtD
Linagliptin—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000599	0.00253	CcSEcCtD
Linagliptin—Myalgia—Indinavir—acquired immunodeficiency syndrome	0.000599	0.00253	CcSEcCtD
Linagliptin—ABCB1—retina—acquired immunodeficiency syndrome	0.000595	0.0206	CbGeAlD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000595	0.00251	CcSEcCtD
Linagliptin—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000591	0.0205	CbGeAlD
Linagliptin—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000588	0.00248	CcSEcCtD
Linagliptin—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000588	0.00248	CcSEcCtD
Linagliptin—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000586	0.00247	CcSEcCtD
Linagliptin—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000585	0.00247	CcSEcCtD
Linagliptin—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000581	0.00245	CcSEcCtD
Linagliptin—Cough—Efavirenz—acquired immunodeficiency syndrome	0.00058	0.00245	CcSEcCtD
Linagliptin—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000574	0.00242	CcSEcCtD
Linagliptin—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000569	0.0024	CcSEcCtD
Linagliptin—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000566	0.00239	CcSEcCtD
Linagliptin—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000566	0.00239	CcSEcCtD
Linagliptin—Myalgia—Efavirenz—acquired immunodeficiency syndrome	0.000566	0.00239	CcSEcCtD
Linagliptin—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000566	0.00239	CcSEcCtD
Linagliptin—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000566	0.00239	CcSEcCtD
Linagliptin—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000566	0.00239	CcSEcCtD
Linagliptin—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000564	0.00238	CcSEcCtD
Linagliptin—CYP3A4—blood—acquired immunodeficiency syndrome	0.000563	0.0195	CbGeAlD
Linagliptin—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000563	0.00237	CcSEcCtD
Linagliptin—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000562	0.00237	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000562	0.00237	CcSEcCtD
Linagliptin—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00056	0.00236	CcSEcCtD
Linagliptin—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00056	0.00236	CcSEcCtD
Linagliptin—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000559	0.00236	CcSEcCtD
Linagliptin—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000558	0.00235	CcSEcCtD
Linagliptin—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000556	0.00235	CcSEcCtD
Linagliptin—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000555	0.00234	CcSEcCtD
Linagliptin—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000548	0.00231	CcSEcCtD
Linagliptin—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000542	0.00229	CcSEcCtD
Linagliptin—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000542	0.00228	CcSEcCtD
Linagliptin—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000542	0.00228	CcSEcCtD
Linagliptin—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.00054	0.00228	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000533	0.00225	CcSEcCtD
Linagliptin—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000528	0.00223	CcSEcCtD
Linagliptin—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000527	0.00222	CcSEcCtD
Linagliptin—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000525	0.00222	CcSEcCtD
Linagliptin—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000523	0.00221	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000523	0.00221	CcSEcCtD
Linagliptin—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000523	0.0022	CcSEcCtD
Linagliptin—Rash—Didanosine—acquired immunodeficiency syndrome	0.000516	0.00218	CcSEcCtD
Linagliptin—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000516	0.00218	CcSEcCtD
Linagliptin—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000516	0.00218	CcSEcCtD
Linagliptin—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000516	0.00217	CcSEcCtD
Linagliptin—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000513	0.00217	CcSEcCtD
Linagliptin—Headache—Didanosine—acquired immunodeficiency syndrome	0.000513	0.00216	CcSEcCtD
Linagliptin—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000504	0.00213	CcSEcCtD
Linagliptin—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000504	0.00212	CcSEcCtD
Linagliptin—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000501	0.00211	CcSEcCtD
Linagliptin—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000501	0.00211	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000497	0.0021	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000496	0.00209	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000494	0.00209	CcSEcCtD
Linagliptin—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000494	0.00208	CcSEcCtD
Linagliptin—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000494	0.00208	CcSEcCtD
Linagliptin—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000491	0.00207	CcSEcCtD
Linagliptin—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000491	0.00207	CcSEcCtD
Linagliptin—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000488	0.00206	CcSEcCtD
Linagliptin—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000486	0.00205	CcSEcCtD
Linagliptin—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000482	0.00203	CcSEcCtD
Linagliptin—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000482	0.00203	CcSEcCtD
Linagliptin—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000479	0.00202	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000479	0.00202	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000473	0.002	CcSEcCtD
Linagliptin—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000471	0.00199	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000468	0.00198	CcSEcCtD
Linagliptin—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000466	0.00197	CcSEcCtD
Linagliptin—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000464	0.00196	CcSEcCtD
Linagliptin—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000464	0.00196	CcSEcCtD
Linagliptin—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000464	0.00196	CcSEcCtD
Linagliptin—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000461	0.00194	CcSEcCtD
Linagliptin—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.00046	0.00194	CcSEcCtD
Linagliptin—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.00046	0.00194	CcSEcCtD
Linagliptin—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000459	0.00194	CcSEcCtD
Linagliptin—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000457	0.0158	CbGeAlD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000457	0.00193	CcSEcCtD
Linagliptin—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000456	0.00192	CcSEcCtD
Linagliptin—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000449	0.0019	CcSEcCtD
Linagliptin—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000449	0.00189	CcSEcCtD
Linagliptin—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000449	0.00189	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000448	0.00189	CcSEcCtD
Linagliptin—Rash—Stavudine—acquired immunodeficiency syndrome	0.000448	0.00189	CcSEcCtD
Linagliptin—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000448	0.00189	CcSEcCtD
Linagliptin—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000446	0.00188	CcSEcCtD
Linagliptin—Headache—Stavudine—acquired immunodeficiency syndrome	0.000445	0.00188	CcSEcCtD
Linagliptin—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000444	0.00187	CcSEcCtD
Linagliptin—Rash—Abacavir—acquired immunodeficiency syndrome	0.000441	0.00186	CcSEcCtD
Linagliptin—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000441	0.00186	CcSEcCtD
Linagliptin—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000441	0.00186	CcSEcCtD
Linagliptin—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.00044	0.0153	CbGeAlD
Linagliptin—Headache—Abacavir—acquired immunodeficiency syndrome	0.000439	0.00185	CcSEcCtD
Linagliptin—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000438	0.00185	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000437	0.00185	CcSEcCtD
Linagliptin—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000431	0.00182	CcSEcCtD
Linagliptin—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000428	0.00181	CcSEcCtD
Linagliptin—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000423	0.0147	CbGeAlD
Linagliptin—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000423	0.00179	CcSEcCtD
Linagliptin—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000423	0.00178	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000421	0.00178	CcSEcCtD
Linagliptin—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000418	0.0145	CbGeAlD
Linagliptin—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000415	0.00175	CcSEcCtD
Linagliptin—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000412	0.00174	CcSEcCtD
Linagliptin—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000411	0.00173	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000402	0.00169	CcSEcCtD
Linagliptin—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.0004	0.00169	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000399	0.00168	CcSEcCtD
Linagliptin—ABCB1—blood—acquired immunodeficiency syndrome	0.000398	0.0138	CbGeAlD
Linagliptin—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000395	0.00167	CcSEcCtD
Linagliptin—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000393	0.00166	CcSEcCtD
Linagliptin—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000389	0.00164	CcSEcCtD
Linagliptin—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000389	0.00164	CcSEcCtD
Linagliptin—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000387	0.00163	CcSEcCtD
Linagliptin—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000385	0.0134	CbGeAlD
Linagliptin—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000384	0.0133	CbGeAlD
Linagliptin—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000383	0.00161	CcSEcCtD
Linagliptin—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.00161	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000381	0.00161	CcSEcCtD
Linagliptin—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000377	0.00159	CcSEcCtD
Linagliptin—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000371	0.00157	CcSEcCtD
Linagliptin—ABCB1—vagina—acquired immunodeficiency syndrome	0.000369	0.0128	CbGeAlD
Linagliptin—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000367	0.00155	CcSEcCtD
Linagliptin—Rash—Indinavir—acquired immunodeficiency syndrome	0.000362	0.00153	CcSEcCtD
Linagliptin—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000362	0.00153	CcSEcCtD
Linagliptin—Headache—Indinavir—acquired immunodeficiency syndrome	0.00036	0.00152	CcSEcCtD
Linagliptin—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000355	0.0015	CcSEcCtD
Linagliptin—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000354	0.00149	CcSEcCtD
Linagliptin—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00035	0.00148	CcSEcCtD
Linagliptin—ABCB1—lung—acquired immunodeficiency syndrome	0.000349	0.0121	CbGeAlD
Linagliptin—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000342	0.00144	CcSEcCtD
Linagliptin—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000342	0.00144	CcSEcCtD
Linagliptin—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00034	0.00144	CcSEcCtD
Linagliptin—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00034	0.00143	CcSEcCtD
Linagliptin—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000329	0.00139	CcSEcCtD
Linagliptin—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000327	0.00138	CcSEcCtD
Linagliptin—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000327	0.00138	CcSEcCtD
Linagliptin—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000325	0.00137	CcSEcCtD
Linagliptin—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000325	0.00137	CcSEcCtD
Linagliptin—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000323	0.0112	CbGeAlD
Linagliptin—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000316	0.00133	CcSEcCtD
Linagliptin—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000311	0.0108	CbGeAlD
Linagliptin—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000303	0.00128	CcSEcCtD
Linagliptin—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000302	0.00128	CcSEcCtD
Linagliptin—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000302	0.00127	CcSEcCtD
Linagliptin—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000301	0.00127	CcSEcCtD
Linagliptin—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000291	0.00123	CcSEcCtD
Linagliptin—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000291	0.00123	CcSEcCtD
Linagliptin—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.00122	CcSEcCtD
Linagliptin—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000278	0.00117	CcSEcCtD
Linagliptin—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000278	0.00117	CcSEcCtD
Linagliptin—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.00117	CcSEcCtD
Linagliptin—ABCB1—brain—acquired immunodeficiency syndrome	0.000247	0.00857	CbGeAlD
Linagliptin—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000239	0.00828	CbGeAlD
